Mateon Therapeutics, now known as Oncotelic Therapeutics, was founded with a core mission to develop innovative small molecule drugs targeting cancer and infectious diseases. Based in South San Francisco, California, the company aims to provide effective treatment solutions on a global scale. Their product portfolio includes advanced immuno-oncology therapies designed to harness the body's immune system to combat malignancies and severe infections.

Notable figures associated with Oncotelic Therapeutics include experts in oncology and pharmacology who have significantly contributed to the company's research and development efforts. The company has secured investments from prominent venture capital firms, bolstering its financial stability and enabling extensive clinical trials. Key achievements include the successful development of several promising drug candidates that have shown efficacy in preclinical and clinical studies, positioning Oncotelic as a significant player in the biotech industry.